# Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.

> **NCT05931484** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Forest Hills Lab** · enrollment: 32 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Gemfibrozil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05931484
- **Lead sponsor:** Forest Hills Lab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-11-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931484, "Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05931484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*